Meeting of the National Competent Authorities on Pricing and Reimbursement and Public Healthcare Payers (NCAPR) held in Brussels on Friday 19 April 2024. Read the news published by the European Commission on 19 April 2024.
The 2019 voluntary scheme for branded medicines pricing and access (voluntary scheme) is a non-contractual voluntary agreement between DHSC and ABPI. The ABPI is the representative body of the pharmaceutical industry in the UK. It aims to provide stability and...
New voluntary scheme for branded medicines pricing, access and growth (VPAG) will boost nation’s health, save NHS £14 billion and support research investment. This scheme is an agreement between DHSC, NHS England and ABPI to support...
The first and currently only gene therapy for children with an ultra-rare genetic disorder has been recommended by NICE in a final draft guidance published on the 23rd of March 2023. Children with the condition, called aromatic L-amino...
On the 26th of January 2023, NICE issued a final appraisal document recommending the treatment be made routinely available on the NHS for suitable patients. People with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal...
The government, NHS England and the pharmaceutical industry will begin negotiating the successor to the voluntary scheme for branded medicines, pricing and access (VPAS). Published on the 4th of May 2023. Find out more here.
A new study published in Healthcare evaluates the factors associated with differences in treatment costs for orphan and non-orphan drugs in the United States. Recently, there has been growing concern about the affordability of orphan drugs (ODs)....
A new article published in Expert Review of Pharmacoeconomics & Outcomes Research reviews methodological recommendations for the economic evaluation of cell and gene therapies, and the extent to which these recommendations have been implemented in published evaluations.
Dans une interview pour Espace Social Européen, le président du Leem fait le point sur l’actualité du secteur tout en revenant, sans détour, sur l’état des relations entre les pouvoirs publics et les industriels à...
Certains avis sur des médicaments rendus par la commission de la transparence de la Haute Autorité de santé (HAS) donnent lieu à des critiques. L’institution souhaite lever des incompréhensions. Elle ne peut laisser croire en...
